Difference between revisions of "Cemiplimab (Libtayo)"
Jump to navigation
Jump to search
m |
m |
||
| Line 2: | Line 2: | ||
From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-monoclonal-antibody-regn2810 NCI Drug Dictionary]: A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. | From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-monoclonal-antibody-regn2810 NCI Drug Dictionary]: A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. | ||
| − | = | + | ==Diseases for which it is used== |
| − | ===[[Cutaneous squamous cell carcinoma] | + | *[[Cutaneous squamous cell carcinoma]] |
| − | |||
| + | ==History of changes in FDA indication== | ||
| + | *9/28/2018: Initial approval "for patients with [[Cutaneous squamous cell carcinoma|metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC]] who are not candidates for curative surgery or curative radiation." | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' REGN2810 | *'''Code name:''' REGN2810 | ||
| + | *'''Generic name:''' cemiplimab-rwlc | ||
| + | *'''Brand name:''' Libtayo | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 17: | Line 20: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
| − | [[Category: | + | [[Category:Cutaneous squamous cell carcinoma medications]] |
| + | [[Category:FDA approved in 2018]] | ||
Revision as of 15:39, 2 October 2018
Mechanism of action
From NCI Drug Dictionary: A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways.
Diseases for which it is used
History of changes in FDA indication
- 9/28/2018: Initial approval "for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation."
Also known as
- Code name: REGN2810
- Generic name: cemiplimab-rwlc
- Brand name: Libtayo